Rafael Holdings climbs on completion of pivotal Phase 3 rare disease trial
Rafael Holdings (NYSE:RFL) reported its third-quarter fiscal 2026 financial results alongside a critical clinical milestone, finalizing the active clinical phase of its lead rare disease program and clearing the path for a regulatory submission later this year.
The Newark, New Jersey-based biopharmaceutical company confirmed the completion of the "last patient, last visit" milestone in its pivotal Phase 3 TransportNPC clinical trial.
The global multi-center study is evaluating Trappsol Cyclo, an intravenous formulation of hydroxypropyl-beta-cyclodextrin, as a potential treatment for Niemann-Pick Disease Type C1 (NPC1)—a rare, progressive, and fatal genetic lysosomal storage disorder that causes severe neurological and systemic decline.
Following a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration, corporate leadership announced that the company is on track to officially submit its comprehensive NDA package to the regulator during the second half of calendar year 2026.
Topline data from the main study cohort is scheduled to be unblinded and presented at upcoming medical symposiums over the same multi-week period.
The operational focus on Trappsol Cyclo follows Rafael's corporate restructure, which concluded with the total acquisition and consolidation of clinical-stage developer Cyclo Therapeutics last year.
The absorption of the entity heavily shifted Rafael's financial reporting metrics for the three-month period ended April 30, 2026.
Financially, Rafael's third-quarter research and development (R&D) expenses increased to $4.9 million, up from $3 million in the prior-year period.
For the first nine months of fiscal 2026, cumulative R&D spending expanded to $16.9 million compared to $5.3 million in fiscal 2025.
Management attributed the steep upward trajectory exclusively to the non-recurring clinical costs inherited from the final stages of the international TransportNPC trial.
Conversely, corporate streamline efficiencies allowed third-quarter general and administrative (G&A) expenses to fall to $2.1 million from $3.2 million a year earlier, while nine-month G&A narrowed down to $7.3 million from $8.3 million.
The net loss attributable to Rafael Holdings for the fiscal third quarter was $4.2 million, or $0.08 per diluted share.
This represents a structural improvement over the net loss of $4.8 million, or $0.19 per diluted share, recorded during the third quarter of fiscal 2025.
For the combined nine-month tracking period, Rafael’s cumulative net loss sat at $20.5 million, or $0.40 per share, compared to a net loss of $18.4 million, or $0.73 per share, during the first three quarters of fiscal 2025.
On the balance sheet, the company maintained a capital runway consisting of $30.5 million in cash, cash equivalents, and short-term investments, down from $37.8 million at the end of the preceding fiscal second quarter.
